Literature DB >> 8033095

p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer.

R M Elledge1, G M Clark, S A Fuqua, Y Y Yu, D C Allred.   

Abstract

Nuclear accumulation of p53 protein is associated with a poorer clinical outcome in breast cancer patients. Heat shock protein 70 (hsp70) is a chaperone that binds to mutant p53 and consequently could regulate its accumulation or localization. The aims of this study were to determine if the prognostic significance of p53 accumulation was dependent on the type of antibody used for detection and whether hsp70 was associated with this accumulation. Node-negative breast tumors (n = 169) were examined by immunohistochemistry for nuclear p53, cytoplasmic or nuclear hsp70, and for p53 gene alteration by single-strand conformation polymorphism analysis. Frozen sections of pulverized breast tumors were stained with five p53 antibodies (240, 1801, 421, BP53-12, and CM1), a cocktail of both 240 and 1801, and the hsp70 antibody C92. Protein level was expressed as the sum of a proportion and intensity score (total 0, 2-8) with > or = 2 defined as positive staining. The cocktail 240/1801 gave the highest rate of positive staining (45%), followed by BP53-12 (35%), 1801 (27%), 240 (25%), CM1 (24%), and 421 (18%), with a high correlation between antibodies. Positive staining with each individual antibody or the cocktail was significantly associated with estrogen receptor and progesterone receptor negativity, age < 50, and high S-phase fraction. Only staining detected by the 240/1801 cocktail was associated with significantly worse overall survival; 85 versus 70% at 5 years for p53-negative compared to p53-positive tumors, respectively (P = 0.02). There was no association between nuclear or cytoplasmic hsp70 staining and accumulation of p53. Patients that were p53-negative/cytoplasmic hsp70-positive had a better overall survival than those that were p53-negative/cytoplasmic hsp70-negative. No other combination of p53 and hsp70 status could further define subsets of patients with a significantly different prognosis compared to p53 status alone. Tumors without a detectable p53 gene alteration by single-strand conformation polymorphism but with accumulated p53 protein did not have relatively increased levels of hsp70. We conclude that in node-negative breast cancer, the cocktail of two antibodies, 240/1801, resulted in the highest rate of positive staining and was most strongly associated with overall survival compared with either antibody alone or with the other individual antibodies. By immunohistochemistry, nuclear accumulation of p53 was not associated with cytoplasmic or nuclear hsp70 levels.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8033095

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Prognostic and Predictive Factors for Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1995-10-31       Impact factor: 4.239

2.  Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies.

Authors:  P Würl; H Taubert; A Meye; D Berger; C Lautenschläger; H J Holzhausen; H Schmidt; H Kalthoff; F W Rath; H Dralle
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  Mortalin is a prognostic factor of gastric cancer with normal p53 function.

Authors:  Koji Ando; Eiji Oki; Yan Zhao; Ayae Ikawa-Yoshida; Hiroyuki Kitao; Hiroshi Saeki; Yasue Kimura; Satoshi Ida; Masaru Morita; Tetsuya Kusumoto; Yoshihiko Maehara
Journal:  Gastric Cancer       Date:  2013-07-05       Impact factor: 7.370

4.  A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.

Authors:  Suleiman Massarweh; Yee L Tham; Jian Huang; Krystal Sexton; Heidi Weiss; Anna Tsimelzon; Amanda Beyer; Mothaffar Rimawi; Wei Yen Cai; Susan Hilsenbeck; Suzanne Fuqua; Richard Elledge
Journal:  Breast Cancer Res Treat       Date:  2011-07-27       Impact factor: 4.872

5.  Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53.

Authors:  J E Hundley; S K Koester; D A Troyer; S G Hilsenbeck; M A Subler; J J Windle
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

6.  HspBP1 levels are elevated in breast tumor tissue and inversely related to tumor aggressiveness.

Authors:  Ana Paula Souza; Caroline Albuquerque; Carolina Torronteguy; Antonio Frasson; Fabio Maito; Luciana Pereira; Vinícius Duval da Silva; Felipe Zerwes; Deborah Raynes; Vince Guerriero; Cristina Bonorino
Journal:  Cell Stress Chaperones       Date:  2008-11-06       Impact factor: 3.667

7.  Prognosis for Survival of Young Women with Breast Cancer by Quantitative p53 Immunohistochemistry.

Authors:  David E Axelrod; Kinsuk Shah; Qifeng Yang; Bruce G Haffty
Journal:  Cancer Clin Oncol       Date:  2012

8.  Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer.

Authors:  Suleiman Massarweh; Jessica Moss; Chi Wang; Edward Romond; Stacey Slone; Heidi Weiss; Rouzan G Karabakhtsian; Dana Napier; Esther P Black
Journal:  Future Oncol       Date:  2014-12       Impact factor: 3.404

9.  p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma.

Authors:  S Bosari; G Viale; M Roncalli; D Graziani; G Borsani; A K Lee; G Coggi
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

10.  Heat shock cognate 70 protein secretion as a new growth arrest signal for cancer cells.

Authors:  P Nirdé; D Derocq; M Maynadier; M Chambon; I Basile; M Gary-Bobo; M Garcia
Journal:  Oncogene       Date:  2009-10-05       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.